CompletedPhase 1

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

United States80 participantsStarted 2020-09-29

Plain-language summary

This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vascular dementia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Patients older than 18 years and diagnosed with mild cognitive impairment (MCI), Alzheimer's disease (AD), or vascular cognitive impairment and/or dementia (VaD). Exclusion Criteria: * Children and subjects with other diagnoses than those mentioned in the inclusion criteria. * Patients without the means to visit the clinic on the assigned dates. * Patients who are pregnant or are expecting to become pregnant.

What they're measuring

retinopathy features identification

Timeframe: 12 months

Trial details

NCT IDNCT04567745

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-30

View on ClinicalTrials.gov More Mild Cognitive Impairment trials